NEWS HIGHLIGHTSMedia Articles Related to Namenda (Memantine)
Alzheimer's Disease
Source: MedicineNet Immunizations Specialty [2017.06.01]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 12:00:00 AM
Last Editorial Review: 6/1/2017 12:00:00 AM
Dementia, Alzheimer's Disease, and Aging Brains
Source: MedicineNet Hydrocephalus Specialty [2016.08.01]
Title: Dementia, Alzheimer's Disease, and Aging Brains
Category: Slideshows
Created: 12/3/2009 10:07:00 AM
Last Editorial Review: 8/1/2016 12:00:00 AM
Alzheimer's Disease Symptoms & Early Diagnosis
Source: MedicineNet memantine Specialty [2016.07.27]
Title: Alzheimer's Disease Symptoms & Early Diagnosis
Category: Slideshows
Created: 9/21/2015 12:00:00 AM
Last Editorial Review: 7/27/2016 12:00:00 AM
Caring for Someone With Alzheimer's Disease
Source: MedicineNet memantine Specialty [2016.05.16]
Title: Caring for Someone With Alzheimer's Disease
Category: Slideshows
Created: 2/16/2010 2:51:00 PM
Last Editorial Review: 5/16/2016 12:00:00 AM
7 Alzheimer's Disease Stages and Symptoms
Source: MedicineNet Advance Medical Directives Specialty [2016.05.12]
Title: 7 Alzheimer's Disease Stages and Symptoms
Category: Diseases and Conditions
Created: 7/30/2014 12:00:00 AM
Last Editorial Review: 5/12/2016 12:00:00 AM
Published Studies Related to Namenda (Memantine)
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses
using realistic definitions of response. [2014]
analysis of memantine... CONCLUSIONS: New definitions of clinical worsening based on MIDs represent a more
Genotype variant associated with add-on memantine in bipolar II disorder. [2014]
Memantine is a non-competitive N-methyl-d-asparate (NMDA) receptor antagonist
with a mood-stabilizing effect. We investigated whether using valproic acid (VPA)
plus add-on memantine to treat bipolar II disorder (BP-II) is more effective than
using VPA alone (VPAÂ +Â Pbo)...
Vitamin E and memantine in Alzheimer's disease: clinical trial methods and
baseline data. [2014]
and (iv) placebo in delaying clinical progression in AD... CONCLUSION: This large multicenter trial will address the unanswered question of
Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome
(FXTAS): a double-blind brain potential study. [2014]
Older FMR1 premutation carriers may develop fragile X-associated tremor/ataxia
syndrome (FXTAS), a neurodegenerative disorder manifesting cognitive deficits
that often subsequently progress to dementia... Additional studies of memantine,
perhaps in combination with other therapeutic agents, appear warranted, as
symptomatic treatments and neuroprotective treatments are both needed for this
recently recognized neurodegenerative disorder.
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for
the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or
Clinical Trials Related to Namenda (Memantine)
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction? [Recruiting]
Many patients with epilepsy have memory deficits in the setting of otherwise normal
intelligence. Unfortunately, the treatment options for memory dysfunction in patients with
epilepsy are limited. The investigators are conducting a study to evaluate the effects of
memantine for the treatment of verbal memory dysfunction in subjects with
localization-related seizures. The study involves randomization to memantine therapy or
placebo, with cognitive testing and EEG pre- and post-treatment, as well as after an
open-label memantine treatment phase.
The primary aim of this study is to evaluate the efficacy of memantine for the treatment of
verbal memory dysfunction in subjects with left temporal lobe epilepsy. The investigators
expect that verbal memory task performance will improve in those taking memantine, but not
in those taking a placebo.
The investigators propose that the expected benefit of memantine is specific to verbal
memory in subjects with left temporal lobe seizures, rather than representing an overall
improvement in cognitive function. The investigators expect no improvement on other
cognitive tasks in either the memantine or placebo groups.
The investigators will evaluate whether subjects with left temporal lobe epilepsy and memory
difficulties have self-reported improvement in memory while taking memantine. The
investigators expect improvement of self-rated memory function on the Quality of Life in
Epilepsy Patient Inventory (QOLIE-89) in the memantine group, but no change on this scale in
the placebo group.
Down Syndrome Memantine Follow-up Study [Recruiting]
The purpose of this research study is to learn if the medication Memantine Hydrochloride
(the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto
Costa and his research team want to see if a 16-week treatment with this medication can
improve the participant's ability to learn and remember things. In this study, memantine
hydrochloride will be used. Thus, the researchers want to learn whether the study drug can
help improve memory in young adults with Down syndrome. To test the effect of the study
medicine, half of the people in the study will receive the study medicine and half will
receive a placebo (an inactive substance). Memantine is an approved medication to treat
memory and thinking problems in persons with Alzheimer disease. However, little is known
about the effect of this medication in persons with Down syndrome and it has not been
approved for use in persons with Down syndrome.
The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? [Not yet recruiting]
The purpose of this study is to determine whether memantine will enhance the therapeutic of
effect on depression and prevent memory and other cognitive problems caused by ECT.
A Study of Memantine Hydrochloride (Namenda�) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders [Active, not recruiting]
The main objective of this study is to evaluate the safety and effectiveness of memantine
(Namenda®) for cognitive and behavioral impairment in adults ages 18-50 years with autism
spectrum disorders (ASD). This is an exploratory, 12-week, pilot study, seeking to determine
whether Namenda is efficacious and well tolerated in the treatment of adults with ASD. The
study results will be used to generate hypotheses for a larger randomized controlled
clinical trial with explicit hypotheses and sufficient statistical power.
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease [Completed]
The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or
the combination will significantly delay clinical progression in mild to moderately demented
patients with Alzheimer's disease compared to placebo.
Reports of Suspected Namenda (Memantine) Side Effects
Confusional State (7),
Dizziness (5),
Abnormal Behaviour (5),
Tremor (5),
Movement Disorder (4),
Drug Interaction (4),
OFF Label USE (4),
Asthenia (4),
Thinking Abnormal (3),
Balance Disorder (3), more >>
|
